At a glance
ClinicalIndex Comparison RecordN/ACompleted· 72 enrolled
Drug / intervention
SYALOX® 300 Plus +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double Blind, Placebo Controlled Trial to Evaluate the Effects of a Nutraceutical Containing High-Molecular-Weight Hyaluronic Acid (HA) and Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) in Patients Affected by Knee Osteoarthritis
In Brief
A clinical study evaluating SYALOX® 300 Plus and Placebo for Knee Osteoarthritis. Completed, enrolled 72 participants across 1 site.
Detailed Summary
Double blind, placebo controlled trial to evaluate the effects of a nutraceutical containing high-molecular-weight hyaluronic acid (HA) and acetyl-11-keto-beta-boswellicacid (AKBA) in patients affected by knee osteoarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Osteoarthritis
CountriesRomania
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionApr 2019
Study CompletionJul 2019
TodayJul 2026
First PostedAug 2, 2018
Enrollment StartAug 22, 2018
Primary CompletionApr 10, 2019
Study CompletionJul 26, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.9 years ago
Interventions
SYALOX® 300 Plusdietary
Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
Placebodietary
Placebo comparator. No chemical effect expected